Moving towards personalized treatments of immune-related adverse events

Esfahani, Khashayar; Elkrief, Arielle; Calabrese, Cassandra; Lapointe, Réjean; Hudson, Marie; Routy, Bertrand; Miller, Wilson H.; Calabrese, Leonard

doi:10.1038/s41571-020-0352-8

Cited by 352Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

Moving towards personalized treatments of immune-related adverse events

Esfahani, Khashayar, Elkrief, Arielle, Calabrese, Cassandra, Lapointe, Réjean, Hudson, Marie, Routy, Bertrand, Miller, Wilson H., Calabrese, Leonard·2020·Nature Reviews Clinical Oncology

DOI 10.1038/s41571-020-0352-8

Open this paper in CoChat — free account

Abstract

The enhancement of immune responses upon treatment with immune checkpoint inhibitors can have the desired outcome of reinvigorating antitumour immune surveillance, but often at the expense of immune-related adverse events (irAEs). This novel disease entity often prompts comparisons with, and extrapolation of treatment approaches from, primary autoimmune disorders. Accordingly, current treatment guidelines for irAEs make generic recommendations adapted from the literature describing primary autoimmune diseases, without taking into consideration the substantial disparity of the immunohistopathological findings within each organ affected by an irAE. The treatment modalities themselves are complex and have many potential drawbacks, such as serious and rarely fatal infections, drug toxicities overlapping with irAEs and the risk of compromising cancer immune surveillance. Herein, we provide an overview of key cellular and soluble immunological factors mediating irAEs and propose a model integrating this knowledge with the immunohistopathological findings of the affected organs for a personalized decision-making process for each patient.

Integrity signals

Registry

Crossref · 10.1038/s41571-020-0352-8

Cites

185 of 185 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

ICI targeting PD-1 and CTLA-4 is clinically effective in enhancing T-cell-mediated antitumor responses.
“Although proving to be clinically effective in enhancing T-cell-mediated antitumor responses”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [168]

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · see citing works
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · see citing works
Self-citation
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385 · see citing works
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · see citing works
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532 · see citing works
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713 · see citing works
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · see citing works
Self-citation
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature reviews. Immunology · doi:10.1038/nri1604 · Cited by 3,480 · see citing works
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works
Transforming growth factor-β induces development of the TH17 lineage
Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., & Weaver, C. T. (2006) · Nature · doi:10.1038/nature04754 · Cited by 3,087 · see citing works
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731 · see citing works
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674 · see citing works
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374 · see citing works
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367 · see citing works
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · see citing works
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155 · see citing works
Gut microbiome structure and metabolic activity in inflammatory bowel disease
Franzosa, E. A., Sirota-Madi, A., Avila-Pacheco, J., Fornelos, N., Haiser, H. J., Reinker, S., Vatanen, T., Hall, A. B., Mallick, H., McIver, L. J., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0306-4 · Cited by 1,995 · see citing works
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992 · see citing works
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942 · see citing works
B cells are associated with survival and immunotherapy response in sarcoma
Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1906-8 · Cited by 1,942 · see citing works
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C., Simon, A., & van der Meer, J. V. D. (2012) · Nature reviews. Drug discovery · doi:10.1038/nrd3800 · Cited by 1,813 · see citing works
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Sandborn, W. J., Su, C. G., Sands, B. E., D’Haens, G., Vermeire, S., Schreiber, S., Danese, S., Feagan, B. G., Reinisch, W., Niezychowski, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606910 · Cited by 1,783 · see citing works
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617 · see citing works
Interleukin-1 and IL-23 Induce Innate IL-17 Production from γδ T Cells, Amplifying Th17 Responses and Autoimmunity
Sutton, C. E., Lalor, S. J., Sweeney, C. M., Brereton, C. F., Lavelle, E. C., & Mills, K. H. G. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.001 · Cited by 1,553 · see citing works
The IL-1 family: regulators of immunity
Sims, J. E., & Smith, D. E. (2010) · Nature reviews. Immunology · doi:10.1038/nri2691 · Cited by 1,416 · see citing works
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Haslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413 · see citing works
Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337 · see citing works
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310 · see citing works
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215 · see citing works
Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin
Kazatchkine, M. D., & Kaveri, S. V. (2001) · New England Journal of Medicine · doi:10.1056/nejmra993360 · Cited by 1,212 · see citing works
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
Hirano, T., Ishihara, K., & Hibi, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203551 · Cited by 1,187 · see citing works
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158 · see citing works
Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.
Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0006 · Cited by 1,071 · see citing works
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064 · see citing works
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · see citing works
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
Khoja, L., Day, D., Chen, T. W., Siu, L. L., & Hansen, A. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx286 · Cited by 937 · see citing works
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
Teng, M. W. L., Bowman, E. P., McElwee, J. J., Smyth, M. J., Casanova, J., Cooper, A. M., & Cua, D. J. (2015) · Nature Medicine · doi:10.1038/nm.3895 · Cited by 876 · see citing works
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer
Lesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862 · see citing works
A Proposed Classification of the Immunological Diseases
McGonagle, D., & McDermott, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030297 · Cited by 841 · see citing works
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836 · see citing works
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817 · see citing works
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B. E., Bradley, J. D., Gruben, D. C., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310476 · Cited by 778 · see citing works
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740 · see citing works
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody
Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715 · see citing works
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Ghoreschi, K., Jesson, M. I., Xiong, L., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003668 · Cited by 642 · see citing works
Dermatologic Reactions to Immune Checkpoint Inhibitors
Sibaud, V. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0336-3 · Cited by 631 · see citing works
Molecular mimicry and autoimmunity
Rojas, M., Restrepo-Jiménez, P., Monsalve, D. M., Pacheco, Y., Acosta-Ampudia, Y., Ramírez-Santana, C., Leung, P. S. C., Ansari, A. A., Gershwin, M. E., & Anaya, J.-M. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.012 · Cited by 627 · see citing works
The pathogenicity of Th17 cells in autoimmune diseases
Yasuda, K., Takeuchi, Y., & Hirota, K. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00733-8 · Cited by 559 · see citing works
Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway
Wei, L.-H., Kuo, M.-L., Chen, C.-A., Chou, C.-H., Lai, K.-B., Lee, C.-N., & Hsieh, C.-Y. (2003) · Oncogene · doi:10.1038/sj.onc.1206226 · Cited by 536 · see citing works
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Mace, T. A., Shakya, R., Pitarresi, J. R., Swanson, B. J., McQuinn, C. W., Loftus, S. N., Nordquist, E., Cruz‐Monserrate, Z., Yu, L., Young, G. S., et al. (2016) · Gut · doi:10.1136/gutjnl-2016-311585 · Cited by 535 · see citing works
When worlds collide: Th17 and Treg cells in cancer and autoimmunity
Knochelmann, H. M., Dwyer, C. J., Bailey, S. R., Amaya, S. M., Elston, D. M., Mazza-McCrann, J. M., & Paulos, C. M. (2018) · Cellular & Molecular Immunology · doi:10.1038/s41423-018-0004-4 · Cited by 535 · see citing works
The Role of IL-17 and related cytokines in inflammatory autoimmune diseases
Kuwabara, T., Ishikawa, F., Kondo, M., & Kakiuchi, T. (2017) · Mediators of Inflammation · doi:10.1155/2017/3908061 · Cited by 519 · see citing works
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Papp, K. A., Blauvelt, A., Bukhalo, M., Gooderham, M., Krueger, J. G., Lacour, J. ‐., Menter, A., Philipp, S., Sofen, H. L., Tyring, S. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607017 · Cited by 514 · see citing works
Autoinflammatory Disease Reloaded: A Clinical Perspective
Kastner, D. L., Aksentijevich, I. A., & Goldbach‐Mansky, R. T. (2010) · Cell · doi:10.1016/j.cell.2010.03.002 · Cited by 505 · see citing works
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review
Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487 · see citing works
High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma
Faje, A. T., Lawrence, D., Flaherty, K., Freedman, C., Fadden, R., Rubin, K., Cohen, J., & Sullivan, R. J. (2018) · Cancer · doi:10.1002/cncr.31629 · Cited by 486 · see citing works
Mechanisms of action of mycophenolate mofetil
Allison, A. (2005) · Lupus · doi:10.1177/096120330501400102 · Cited by 480 · see citing works
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Perez-Ruiz, E., Minute, L., Otano, I., Alvarez, M., Ochoa, M. C., Belsue, V., de Andrea, C., Rodriguez-Ruiz, M. E., Perez-Gracia, J. L., Marquez-Rodas, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1162-y · Cited by 480 · see citing works
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
Brembilla, N. C., Senra, L., & Boehncke, W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01682 · Cited by 477 · see citing works
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III , Double‐Blind, Randomized Controlled Trial
Fleischmann, R., Pangan, A. L., Song, I., Mysler, E., Bessette, L., PETERFY, C. G., Durez, P., Östör, A. J. K., Li, Y., Zhou, Y., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41032 · Cited by 446 · see citing works
Is autoimmunity the Achilles' heel of cancer immunotherapy?
June, C. H., Warshauer, J. T., & Bluestone, J. A. (2017) · Nature Medicine · doi:10.1038/nm.4321 · Cited by 445 · see citing works
Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
Salem, J.-E., Allenbach, Y., Vozy, A., Brechot, N., Johnson, D. B., Moslehi, J. J., & Kerneis, M. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1901677 · Cited by 443 · see citing works
Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects
Schwab, C., Gabrysch, A., Olbrich, P., Patiño, V., Warnatz, K., Wolff, D., Hoshino, A., Kobayashi, M., Imai, K., Takagi, M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.055 · Cited by 441 · see citing works
The Coinhibitory Receptor CTLA-4 Controls B Cell Responses by Modulating T Follicular Helper, T Follicular Regulatory, and T Regulatory Cells
Sage, P. T., Paterson, A. M., Lovitch, S. B., & Sharpe, A. H. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.005 · Cited by 437 · see citing works
The role of IL-6 in host defence against infections: immunobiology and clinical implications
Rose-John, S., Winthrop, K., & Calabrese, L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.83 · Cited by 424 · see citing works
Self-citation
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Das, R., Bar, N., Ferreira, M., Newman, A. M., Zhang, L., Bailur, J. K., Bacchiocchi, A., Kluger, H., Wei, W., Halaban, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96798 · Cited by 423 · see citing works
An Autoinflammatory Disease Due to Homozygous Deletion of the IL1RN Locus
Reddy, S. T., Jia, S., Geoffrey, R., Lorier, R., Suchi, M., Broeckel, U., Hessner, M. J., & Verbsky, J. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809568 · Cited by 408 · see citing works
Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
Cappelli, L. C., Gutierrez, A. K., Bingham, C. O., & Shah, A. A. (2016) · Arthritis Care & Research · doi:10.1002/acr.23177 · Cited by 404 · see citing works
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Berner, F., Bomze, D., Diem, S., Ali, O. H., Fässler, M., Ring, S., Niederer, R., Ackermann, C. J., Baumgaertner, P., Pikor, N., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0402 · Cited by 395 · see citing works
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Tarhini, A. A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0081-1 · Cited by 394 · see citing works
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Bertrand, F., Montfort, A., Marcheteau, E., Imbert, C., Gilhodes, J., Filleron, T., Rochaix, P., Andrieu-Abadie, N., Levade, T., Meyer, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02358-7 · Cited by 384 · see citing works
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
Lim, S. Y., Lee, J. H., Gide, T. N., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E. J., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2795 · Cited by 381 · see citing works
<scp>IL</scp>‐1 and <scp>IL</scp>‐1 regulatory pathways in cancer progression and therapy
Mantovani, A., Barajon, I., & Garlanda, C. (2018) · Immunological Reviews · doi:10.1111/imr.12614 · Cited by 376 · see citing works
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
Griss, J., Bauer, W. M., Wagner, C., Simon, M., Chen, M., Grabmeier‐Pfistershammer, K., Maurer‐Granofszky, M., Roka, F., Penz, T., Bock, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12160-2 · Cited by 373 · see citing works
Interleukin-6 as a Therapeutic Target
Rossi, J., Lu, Z., Jourdan, M., & Klein, B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2291 · Cited by 366 · see citing works
PD-1 is a novel regulator of human B-cell activation
Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2013) · International Immunology · doi:10.1093/intimm/dxs098 · Cited by 365 · see citing works
Circulating CD21 low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells
Rakhmanov, M., Keller, B., Gutenberger, S., Foerster, C., Hoenig, M., Driessen, G. J. A., van der Burg, M., van Dongen, J. J. M., Wiech, E., Visentini, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901984106 · Cited by 334 · see citing works
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217745144 · Cited by 331 · see citing works
IL-6 biology: implications for clinical targeting in rheumatic disease
Calabrese, L., & Rose-John, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.127 · Cited by 329 · see citing works
Self-citation
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
Wollenhaupt, J., Lee, E.-B., Curtis, J. R., Silverfield, J. C., Terry, K. K., Soma, K., Mojcik, C., DeMasi, R., Strengholt, S., Kwok, K. K., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1866-2 · Cited by 321 · see citing works
Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases
Ko, J., Gottlieb, A. B., & Kerbleski, J. F. (2008) · Journal of Dermatological Treatment · doi:10.1080/09546630802441234 · Cited by 314 · see citing works
Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice
Haranaka, K., Satomi, N., & Sakurai, A. (1984) · International Journal of Cancer · doi:10.1002/ijc.2910340219 · Cited by 312 · see citing works
Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment
Tsukamoto, H., Fujieda, K., Miyashita, A., Fukushima, S., Ikeda, T., Kubo, Y., Senju, S., Ihn, H., Nishimura, Y., & Oshiumi, H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0118 · Cited by 305 · see citing works
Immune Checkpoint Inhibitor-Associated Myocarditis
Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 301 · see citing works
Anakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 298 · see citing works
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
Mamlouk, O., Selamet, U., Machado, S., Abdelrahim, M., Glass, W. F., Tchakarov, A. S., Gaber, L. W., Lahoti, A., Workeneh, B., Chen, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0478-8 · Cited by 298 · see citing works
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
Abdel-Wahab, N., Safa, H., Abudayyeh, A., Johnson, D. H., Trinh, V. A., Zobniw, C. M., Lin, H., Wong, M. K., Abdelrahim, M., Gaber, A. O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0585-1 · Cited by 294 · see citing works
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285 · see citing works
Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials.
Campbell, L., Chen, C., Bhagat, S., Parker, R., & Östör, A. (2011) · Rheumatology · doi:10.1093/rheumatology/keq343 · Cited by 280 · see citing works
Enterocolitis due to immune checkpoint inhibitors: a systematic review
Soularue, É., Lepage, P., Colombel, J. F., Coutzac, C., Faleck, D. M., Marthey, L., Collins, M., Chaput, N., Robert, C., & Carbonnel, F. (2018) · Gut · doi:10.1136/gutjnl-2018-316948 · Cited by 263 · see citing works
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Jacquelot, N., Yamazaki, T., Roberti, M. P., Duong, C. P. M., Andrews, M. C., Verlingue, L., Ferrere, G., Becharef, S., Vétizou, M., Daillère, R., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0224-x · Cited by 256 · see citing works
The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz206 · Cited by 246 · see citing works
Self-citation
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Phillips, G. S., Wu, J., Hellmann, M. D., Postow, M. A., Rizvi, N. A., Freites-Martinez, A., Chan, D., Dusza, S., Motzer, R. J., Rosenberg, J. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02141 · Cited by 241 · see citing works
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
Moreira, A., Loquai, C., Pföhler, C., Kähler, K. C., Knauß, S., Heppt, M. V., Gutzmer, R., Dimitriou, F., Meier, F. E., Mitzel-Rink, H., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.033 · Cited by 239 · see citing works
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
Oh, D. Y., Cham, J., Zhang, L., Fong, G., Kwek, S. S., Klinger, M., Faham, M., & Fong, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2324 · Cited by 236 · see citing works
Rheumatic immune-related adverse events from cancer immunotherapy
Calabrese, L. H., Calabrese, C. M., & Cappelli, L. C. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0074-9 · Cited by 233 · see citing works
Self-citation
Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin
Ephrem, A., Misra, N., Hassan, G., Dasgupta, S., Delignat, S., Huyen, J. P. D. V., Chamat, S., Prost, F., Lacroix‐Desmazes, S., Kavery, S. V., et al. (2005) · Clinical and Experimental Medicine · doi:10.1007/s10238-005-0079-y · Cited by 231 · see citing works
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Braaten, T. J., Brahmer, J. R., Forde, P. M., Le, D., Lipson, E. J., Naidoo, J., Schollenberger, M., Zheng, L., Bingham, C. O., Shah, A. A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216109 · Cited by 230 · see citing works
Interleukin-17 Contributes to the Pathogenesis of Autoimmune Hepatitis through Inducing Hepatic Interleukin-6 Expression
Zhao, L., Tang, Y., You, Z., Wang, Q., Liang, S., Han, X., Qiu, D., Wei, J., Liu, Y., Shen, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018909 · Cited by 227 · see citing works
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
Subudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611421113 · Cited by 226 · see citing works
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
Esfahani, K., Buhlaiga, N., Thébault, P., Lapointe, R., Johnson, N. A., & Miller, W. H. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1903064 · Cited by 224 · see citing works
Self-citation
mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging
Perl, A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12756 · Cited by 218 · see citing works
NOD2, an intracellular innate immune sensor involved in host defense and Crohn's disease
Strober, W., & Watanabe, T. (2011) · Mucosal Immunology · doi:10.1038/mi.2011.29 · Cited by 216 · see citing works
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study
Abu-Sbeih, H., Ali, F. S., Alsaadi, D., Jennings, J., Luo, W., Gong, Z., Richards, D. M., Charabaty, A., & Wang, Y. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0461-4 · Cited by 215 · see citing works
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
Fucà, G., Galli, G., Poggi, M., Lo Russo, G., Proto, C., Imbimbo, M., Ferrara, R., Zilembo, N., Ganzinelli, M., Sica, A., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000457 · Cited by 209 · see citing works
Ipilimumab-associated Hepatitis
Johncilla, M. E., Misdraji, J., Pratt, D. S., Agoston, A. T., Lauwers, G. Y., Srivastava, A., & Doyle, L. A. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000453 · Cited by 208 · see citing works
Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab
Scott, S. C., & Pennell, N. A. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.004 · Cited by 202 · see citing works
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
Esfahani, K., & Miller, W. H. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1703047 · Cited by 200 · see citing works
Self-citation
Interferons as pathogenic effectors in autoimmunity
Baccalà, R., Kono, D. H., & Theofilopoulos, A. N. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00252.x · Cited by 199 · see citing works
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
Johnson, D. H., Zobniw, C. M., Trinh, V. A., Ma, J., Bassett, R. L., Abdel‐Wahab, N., Anderson, J. E., Davis, J. E., Joseph, J., Uemura, M. I., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0412-0 · Cited by 196 · see citing works
Immune dysregulation in cancer patients developing immune-related adverse events
Khan, S., Khan, S. A., Luo, X., Fattah, F. J., Saltarski, J. M., Gloria-McCutchen, Y., Lü, R., Xie, Y., Li, Q., Wakeland, E. K., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0155-1 · Cited by 194 · see citing works
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
Suresh, K. S., Naidoo, J., Zhong, Q., Xiong, Y., Mammen, J. S., de Flores, M. D. V., Cappelli, L. C., Balaji, A., Palmer, T., Forde, P. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128654 · Cited by 193 · see citing works
Targeting the tumor microenvironment
Bournazou, E., & Bromberg, J. (2013) · JAK-STAT · doi:10.4161/jkst.23828 · Cited by 191 · see citing works
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
de Moel, E. C., Rozeman, E. A., Kapiteijn, E. H., Verdegaal, E. M. E., Grummels, A., Bakker, J. A., Huizinga, T. W. J., Haanen, J. B., Toes, R. E. M., & van der Woude, D. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0245 · Cited by 191 · see citing works
Systemic use of tumor necrosis factor alpha as an anticancer agent
Roberts, N. J., Zhou, S., Diaz, L. A., & Holdhoff, M. (2011) · Oncotarget · doi:10.18632/oncotarget.344 · Cited by 178 · see citing works
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
Lu, C., Talukder, A. M., Savage, N. M., Singh, N., & Liu, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1291106 · Cited by 176 · see citing works
Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions
Nishimoto, N., Ito, K., & Takagi, N. (2010) · Modern Rheumatology · doi:10.3109/s10165-010-0279-5 · Cited by 172 · see citing works
Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
Chmiel, K., Suan, D., Liddle, C., Nankivell, B. J., Ibrahim, R. A., Bautista, C., Thompson, J. F., Fulcher, D. A., & Kefford, R. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2206 · Cited by 163 · see citing works
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
Shoushtari, A. N., Friedman, C. F., Navid-Azarbaijani, P., Postow, M. A., Callahan, M. K., Momtaz, P., Panageas, K. S., Wolchok, J. D., & Chapman, P. B. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2391 · Cited by 157 · see citing works
Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions
Nishimoto, N., Ito, K., & Takagi, N. (2010) · Modern Rheumatology · doi:10.1007/s10165-010-0279-5 · Cited by 154 · see citing works
IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model
Liu, H., Shen, J., & Lü, K. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.128 · Cited by 150 · see citing works
Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies
Kepp, O., Marabelle, A., Zitvogel, L., & Kroemer, G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0272-7 · Cited by 142 · see citing works
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
Badran, Y. R., Cohen, J. V., Brastianos, P. K., Parikh, A. R., Hong, T. S., & Dougan, M. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0711-0 · Cited by 138 · see citing works
Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1
Mammen, A. L., Rajan, A., Pak, K. S., Lehky, T., Casciola-Rosen, L. A., Donahue, R. N., Lepone, L. M., Ζεκερίδου, Α., Pittock, S. J., Hassan, R., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213777 · Cited by 137 · see citing works
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Shiuan, E. F., Beckermann, K. E., Özgün, A., Kelly, C. M., McKean, M. A., McQuade, J. L., Thompson, M. A., Puzanov, I. J., Greer, J. P., Rapisuwon, S., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0210-0 · Cited by 134 · see citing works
Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.
Callahan, M. K., Yang, A., Tandon, S., Xu, Y., Subudhi, S. K., Roman, R., Heine, A. I., Pogoriler, E., Kuk, D., Panageas, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2505 · Cited by 129 · see citing works
Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
Godwin, J. L., Jaggi, S., Sirisena, I., Sharda, P., Rao, A. D., Mehra, R., & Veloski, C. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0245-2 · Cited by 129 · see citing works
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
Gowen, M. F., Giles, K. M., Simpson, D., Tchack, J., Zhou, H., Moran, U., Dawood, Z., Pavlick, A. C., Hu, S., Wilson, M. A., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1452-4 · Cited by 126 · see citing works
Transcriptional Complex Formation of c-Fos, STAT3, and Hepatocyte NF-1α Is Essential for Cytokine-Driven C-Reactive Protein Gene Expression
Nishikawa, T., Hagihara, K., Serada, S., Isobe, T., Matsumura, A., Song, J., Tanaka, T., Kawase, I., Naka, T., & Yoshizaki, K. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3492 · Cited by 119 · see citing works
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy
Tay, R. Y., Blackley, E., McLean, C., Moore, M., Bergin, P., Gill, S., & Haydon, A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.253 · Cited by 119 · see citing works
A balance of interleukin-12 and -23 in cancer
Ngiow, S. F., Teng, M. W. L., & Smyth, M. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.004 · Cited by 116 · see citing works
Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma
Albiges, L. K., Chamming’s, F., Duclos, B., Stern, M., Motzer, R. J., Ravaud, A., & Camus, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds115 · Cited by 113 · see citing works
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V. A., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0682 · Cited by 111 · see citing works
Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
Esfahani, K., Al-Aubodah, T.-A., Thebault, P., Lapointe, R., Hudson, M., Johnson, N. A., Baran, D., Bhulaiga, N., Takano, T., Cailhier, J.-F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12628-1 · Cited by 109 · see citing works
Self-citation
A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events
Naidoo, J., Zhang, J., Lipson, E. J., Forde, P. M., Suresh, K. S., Moseley, K. F., Mehta, S., Kwatra, S. G., Parian, A. M., Kim, A. K., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7268 · Cited by 107 · see citing works
Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis
Hottinger, A. F., Micheli, R. D., Guido, V., Karampera, A., Hagmann, P., & Pasquier, R. D. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000439 · Cited by 105 · see citing works
Intravenous immunoglobulin as clinical immune-modulating therapy
Gilardin, L., Bayry, J., & Kaveri, S. V. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.130375 · Cited by 103 · see citing works
Advanced model systems and tools for basic and translational human immunology
Wagar, L. E., DiFazio, R. M., & Davis, M. M. (2018) · Genome Medicine · doi:10.1186/s13073-018-0584-8 · Cited by 102 · see citing works
Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
Abu‐Sbeih, H., Herrera, L. N., Tang, T., Altan, M., Chaftari, A., Okhuysen, P. C., Jenq, R. R., & Wang, Y. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0714-x · Cited by 94 · see citing works
Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice
Miossec, P. (2017) · RMD Open · doi:10.1136/rmdopen-2016-000284 · Cited by 93 · see citing works
Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature
Calabrese, C. M., Cappelli, L. C., Kostine, M., Kirchner, E., Braaten, T. J., & Calabrese, L. H. (2019) · RMD Open · doi:10.1136/rmdopen-2019-000906 · Cited by 85 · see citing works
Self-citation
Re-examining the Nature and Function of Self-Reactive T cells
Richards, D. M., Kyewski, B., & Feuerer, M. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.12.005 · Cited by 80 · see citing works
Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions
Mariotti, F. R., Quatrini, L., Munari, E., Vacca, P., & Moretta, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00910 · Cited by 75 · see citing works
Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab.
Schindler, K., Harmankaya, K., Kuk, D., Mangana, J., Michielin, O. A., Höeller, C., Dummer, R., Pehamberger, H., Wolchok, J. D., & Postow, M. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9096 · Cited by 71 · see citing works
How steroids steer T cells
Libert, C., & Dejager, L. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.041 · Cited by 69 · see citing works
A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab
Ghosn, J., Vicino, A., Michielin, O. A., Coukos, G., Küntzer, T., & Obéid, M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0429-4 · Cited by 60 · see citing works
Rheumatologic symptoms in oncologic patients on PD-1 inhibitors
Kuswanto, W. F., MacFarlane, L. A., Gedmintas, L., Mulloy, A., Choueiri, T. K., & Bermas, B. L. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.10.018 · Cited by 58 · see citing works
Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports
Yoshino, K., Nakayama, T., Ito, A., Sato, E., & Kitano, S. (2019) · BMC Cancer · doi:10.1186/s12885-019-6138-7 · Cited by 57 · see citing works
Rapamycin inhibition of eosinophil differentiation attenuates allergic airway inflammation in mice
Hua, W., Liu, H., Xia, L., Tian, B., Huang, H., Chen, Z., Ju, Z., Li, W., Chen, Z., & Shen, H. (2015) · Respirology · doi:10.1111/resp.12554 · Cited by 54 · see citing works
Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report
Naqash, A., Yang, L. V., Sanderlin, E., Atwell, D. C., & Walker, P. (2017) · Acta oncologica · doi:10.1080/0284186x.2017.1406668 · Cited by 53 · see citing works
Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy
Ahmed, T., Pandey, R., Shah, B., & Black, J. (2015) · BMJ Case Reports · doi:10.1136/bcr-2014-208102 · Cited by 50 · see citing works
Corticosteroids influence the mortality and morbidity of acute critical illness
Rady, M. Y., Johnson, D. J., Patel, B. M., Larson, J. S., & Helmers, R. A. (2006) · Critical Care · doi:10.1186/cc4971 · Cited by 48 · see citing works
Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.
Weber, J. S., Tang, H. T., Hippeli, L., Qian, M., Wind‐Rotolo, M., Larkin, J., Wolchok, J. D., Sznol, M., Robert, C., Woods, D. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.100 · Cited by 47 · see citing works
Corticosteroids and infliximab impair the performance of interferon-γ release assays used for diagnosis of latent tuberculosis
Edwards, A. J., Gao, Y., Allan, R. N., Ball, D., de Graaf, H., Coelho, T. A. F., Clifford, V., Curtis, N. C., Williams, A. P., Faust, S. N., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209397 · Cited by 44 · see citing works
Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
Zhang, H. C., Luo, W., & Wang, Y. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0532-1 · Cited by 41 · see citing works
Fatal Myocarditis and Rhabdomyositis in a Patient with Stage Iv Melanoma Treated with Combined Ipilimumab and Nivolumab
Saibil, S. D., Bonilla, L., Majeed, H., Sotov, V., Hogg, D., Chappell, M. A., Cybulsky, M. I., & Butler, M. O. (2019) · Current Oncology · doi:10.3747/co.26.4381 · Cited by 38 · see citing works
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanomaPreprint
Griss, J., Bauer, W. M., Wagner, C., Maurer‐Granofszky, M., Simon, M., Chen, M., Steinberger, P., Grabmeier‐Pfistershammer, K., Roka, F., Penz, T., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/478735 · Cited by 37 · see citing works
Structure-Function Analysis of the p35 Subunit of Mouse Interleukin 12
Zou, J. J., Schoenhaut, D. S., Carvajal, D. M., Warrier, R. R., Presky, D. H., Gately, M. K., & Gubler, U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.5864 · Cited by 37 · see citing works
Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient with Non-Small Cell Lung Cancer
Iyoda, T., Kurita, N., Takada, A., Watanabe, H., & Ando, M. (2018) · American Journal of Case Reports · doi:10.12659/ajcr.908570 · Cited by 36 · see citing works
Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI).
Thapa, B., Roopkumar, J., Kim, A. S., Gervaso, L., Patil, P. D., Calabrese, C. M., Khorana, A. A., & Funchain, P. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e14151 · Cited by 36 · see citing works
Self-citation
Varied immuno-related adverse events induced by immune-check point inhibitors — Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6 —
Okiyama, N., & Tanaka, R. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.95 · Cited by 34 · see citing works
Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience
Ahn, S. S., Jung, S. M., Song, J. J., Park, Y., Park, J. Y., & Lee, S. (2018) · Yonsei Medical Journal · doi:10.3349/ymj.2018.59.3.452 · Cited by 32 · see citing works
Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000472 · Cited by 29 · see citing works
Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine
Fixsen, E., Patel, J., Selim, M. A., & Kheterpal, M. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0531 · Cited by 28 · see citing works
Increment Thresholds for Two Nonidentical Flashes*
Herrick, R. M., & Theisen, C. J. (1972) · Journal of the Optical Society of America · doi:10.1364/josa.62.000588 · Cited by 25 · see citing works
JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non–small Cell Lung Cancers
Pitroda, S. P., Stack, M. E., Liu, G.-F., Song, S.-S., Chen, L. L., Liang, H. L., Parekh, A. D., Huang, X., Roach, P., Posner, M. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0667 · Cited by 23 · see citing works
mTOR complexes differentially orchestrates eosinophil development in allergy
Zhu, C., Xia, L., Li, F., Zhou, L., Weng, Q., Li, Z., Wu, Y., Mao, Y., Zhang, C., Wu, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-25358-z · Cited by 23 · see citing works
The interaction between environmental triggers and epigenetics in autoimmunity
Richardson, B. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.04.005 · Cited by 22 · see citing works
Tumor Necrosis Factor and the consequences of its ablation in vivo
Efimov, G. A., Kruglov, A., Tillib, S. V., Kuprash, D. V., & Nedospasov, S. A. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.01.007 · Cited by 21 · see citing works
A multidisciplinary toxicity team for cancer immunotherapy-related adverse events.
Naidoo, J., Cappelli, L. C., Lipson, E. J., Forde, P. M., Sharfman, W. H., Zhang, J., Mammen, J., Moseley, K. F., Suresh, K. S., Mehta, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.6538 · Cited by 20 · see citing works
Myocarditis associated with infliximab
Slattery, E., Ismail, N., Sheridan, J., Eustace, K., Harewood, G. C., & Patchett, S. E. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21546 · Cited by 20 · see citing works
Biomarkers to predict immune-related adverse events with checkpoint inhibitors.
Head, L., Gorden, N. T., Gulick, R. J. V., Amato, C. M., Frazer‐Abel, A. A., Robinson, W. A., Holers, V. M., Messersmith, W. A., & Davis, S. L. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.8_suppl.131 · Cited by 19 · see citing works
Correction to: The pathogenicity of Th17 cells in autoimmune diseases
Yasuda, K., Takeuchi, Y., & Hirota, K. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00746-3 · Cited by 17 · see citing works
Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors
Ornstein, M. C., Calabrese, C. M., Wood, L. S., Kirchner, E., Profusek, P., Allman, K. D., Martin, A. M., Kontzias, A., Grivas, P. D., Garcia, J. A., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.01.021 · Cited by 15 · see citing works
Self-citation
Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma
Spathas, N., Economopoulou, P., Cheila, M., Kotsantis, I., Fanouriakis, A., Kassara, D., & Psyrri, A. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00409 · Cited by 15 · see citing works
Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression
Meti, N., Petrogiannis‐Haliotis, T., & Esfahani, K. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00177 · Cited by 14 · see citing works
Self-citation
New onset or exacerbation of uveitis with infliximab: paradoxical effects?
Iwahashi, C., Ono, H., Haruta, M., Minami, T., Mashimo, H., Shimojo, H., & Ohguro, N. (2019) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2018-000250 · Cited by 14 · see citing works
Cold agglutinin disease as a new immune-related adverse event associated with anti-PD-L1s and its treatment with rituximab
Dutertre, M., de Menthon, M., Noël, N., Albiges, L. K., & Lambotte, O. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.01.009 · Cited by 12 · see citing works
Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) to predict succeeding onset of immune-related adverse events (irAEs).
Kizawa, R., Miura, Y., Oda, Y., Nagaoka, Y., Ozaki, Y., Kondoh, C. N., Moriguchi, S., Takahashi, Y., Ogawa, K., Tanabe-Hashimoto, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e14110 · Cited by 11 · see citing works
Programmed Cell Death Ligand 1–Induced Coma From Diffuse Cerebritis
Desforges, P., Esfahani, K., & Bouganim, N. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.024992 · Cited by 5 · see citing works
Self-citation
The ImmunoTOX multidisciplinary board: A descriptive study of collaborative management of immune-related adverse events
Michot, J., Lappara, A., Simonaggio, A., Danlos, F. X., Belkhir, R., Collins, M., Berdelou, A., Cauquil, C. A., Edhery, S., Pavec, J. L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz265.003 · Cited by 4 · see citing works
[Photocoagulation of papillary neovascularization].
Bonnet, M. (1980) · PubMed · Cited by 2 · see citing works
Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy.
Esfahani, K., Thébault, P., Lapointe, R., Jamal, R., & Miller, W. H. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9561 · Cited by 2 · see citing works
Self-citation
[Phagocyte and antitoxic immunity in suppurative surgical diseases in children].
Ostrovskiĭ, A. D., & Ia, S. (1969) · PubMed · Cited by 1 · see citing works

Flagged first, then by citations

2 of the 187 references couldn’t be matched to a known paper.

Sorted by citations

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648 · see citing works
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02453-x · Cited by 526 · see citing works
Self-citation
Immune-related adverse events of immune checkpoint inhibitors: a review
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 466 · see citing works
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G. R., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · 癌症：英文版 · doi:10.1002/cac2.12539 · Cited by 382 · see citing works
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Hailemichael, Y., Johnson, D. H., Abdel‐Wahab, N., Foo, W. C., Bentebibel, S.-E., Daher, M., Haymaker, C., Wani, K., Saberian, C., Ogata, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.004 · Cited by 365 · see citing works
Understanding and treating the inflammatory adverse events of cancer immunotherapy
Dougan, M., Luoma, A. M., Dougan, S. K., & Wucherpfennig, K. W. (2021) · Cell · doi:10.1016/j.cell.2021.02.011 · Cited by 319 · see citing works
Immune mechanisms of toxicity from checkpoint inhibitors
Wang, S. J., Dougan, S. K., & Dougan, M. L. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.04.002 · Cited by 292 · see citing works
Advancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · 癌症：英文版 · doi:10.1002/cac2.12178 · Cited by 219 · see citing works
Second Near‐Infrared Light‐Activatable Polymeric Nanoantagonist for Photothermal Immunometabolic Cancer Therapy
Xu, C., Jiang, Y., Huang, J., Huang, J., & Pu, K. (2021) · Advanced Materials · doi:10.1002/adma.202101410 · Cited by 158 · see citing works
Corticosteroids and Cancer Immunotherapy
Goodman, R. S., Johnson, D. B., & Balko, J. M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3181 · Cited by 160 · see citing works
Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy
Huppert, L., Green, M. D., Kim, L., Chow, C., Leyfman, Y., Daud, A., & Lee, J. C. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00742-4 · Cited by 123 · see citing works
Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis
Won, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Delgado, P., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111611 · Cited by 137 · see citing works
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 130 · see citing works
Harnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125 · see citing works
The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19
Robinson, P. C., Liew, D. F. L., Liew, J. W., Monaco, C. G., Richards, D. B., Shivakumar, S., Tanner, H. L., & Feldmann, M. (2020) · Med · doi:10.1016/j.medj.2020.11.005 · Cited by 120 · see citing works
The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer
Singh, S., Numan, A., Maddiboyina, B., Arora, S., Riadi, Y., Md, S., Alhakamy, N. A., & Kesharwani, P. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.011 · Cited by 122 · see citing works
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy
Dimitriou, F., Hogan, S. A., Menzies, A. M., Dummer, R., & Long, G. V. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.031 · Cited by 122 · see citing works
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
Verheijden, R. J., van Eijs, M. J. M., May, A. M., van Wijk, F., & Suijkerbuijk, K. P. M. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00380-1 · Cited by 123 · see citing works
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
Jia, X., Geng, L., Jiang, P., Xu, H., Nan, K., Yao, Y., Jiang, L., Sun, H., Qin, T., & Guo, H. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01749-x · Cited by 119 · see citing works
Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature
Tay, S. H., Toh, M. M. X., Thian, Y. L., Vellayappan, B. A., Fairhurst, A., Chan, Y. H., Aminkeng, F., Bharwani, L. D., Huang, Y., Mak, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807050 · Cited by 122 · see citing works
Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies
Zahnreich, S., & Schmidberger, H. (2021) · Cancers · doi:10.3390/cancers13112607 · Cited by 118 · see citing works
Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
Jing, Y., Chen, X., Li, K., Liu, Y., Zhang, Z., Chen, Y., Liu, Y., Wang, Y., Lin, S. H., Diao, L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003779 · Cited by 117 · see citing works
<i>Faecalibacterium prausnitzii</i> Abrogates Intestinal Toxicity and Promotes Tumor Immunity to Increase the Efficacy of Dual CTLA4 and PD-1 Checkpoint Blockade
Gao, Y., Xu, P., Sun, D., Jiang, Y., Lin, X.-L., Han, T., Yu, J., Sheng, C., Chen, H., Hong, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0605 · Cited by 116 · see citing works
Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management
Fleming, B., Edison, P., & Kenny, L. M. (2023) · BMJ · doi:10.1136/bmj-2022-071726 · Cited by 120 · see citing works
Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy
Anscher, M. S., Arora, S., Weinstock, C., Amatya, A., Bandaru, P., Tang, C. Z., Girvin, A. T., Fiero, M. H., Tang, S., Lubitz, R., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.6439 · Cited by 112 · see citing works
Germline variants associated with toxicity to immune checkpoint blockade
Groha, S., Alaiwi, S. A., Xu, W. V., Naranbhai, V., Nassar, A. H., Bakouny, Z., Zarif, T. E., Saliby, R. M., Wan, G., Rajeh, A. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02094-6 · Cited by 114 · see citing works
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
Fa’ak, F., Buni, M., Falohun, A., Lu, H., Song, J., Johnson, D. H., Zobniw, C. M., Trinh, V. A., Awiwi, M. O., Tahon, N. H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006814 · Cited by 111 · see citing works
Beneficial autoimmunity improves cancer prognosis
Zitvogel, L., Perreault, C., Finn, O. J., & Kroemer, G. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00508-x · Cited by 105 · see citing works
European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement
Apalla, Z., Nikolaou, V. A., Fattore, D., Fabbrocini, G., Freites‐Martínez, A., Sollena, P., Lacouture, M. E., Kraehenbuehl, L., Stratigos, A., Peris, K., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17855 · Cited by 108 · see citing works
Augmenting Immunogenic Cell Death and Alleviating Myeloid‐Derived Suppressor Cells by Sono‐Activatable Semiconducting Polymer Nanopartners for Immunotherapy
Ding, M., Zhang, Y., Yu, N., Zhou, J., Zhu, L., Wang, X., & Li, J. (2023) · Advanced Materials · doi:10.1002/adma.202302508 · Cited by 108 · see citing works
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1796002 · Cited by 108 · see citing works
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy
Jing, Y., Zhang, Y., Wang, J., Li, K., Chen, X., Heng, J., Gao, Q., Ye, Y., Zhang, Z., Liu, Y., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab035 · Cited by 102 · see citing works
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)
McKay, R. R., McGregor, B. A., Xie, W., Braun, D. A., Wei, X. X., Kyriakopoulos, C. E., Zakharia, Y., Maughan, B. L., Rose, T. L., Stadler, W. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02295 · Cited by 103 · see citing works
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches
Cortiula, F., Reymen, B. J. T., Peters, S., Mol, P. V., Wauters, E., Vansteenkiste, J., Ruysscher, D. D., & Hendriks, L. E. L. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.013 · Cited by 99 · see citing works
Strategies for improving the management of immune-related adverse events
Naing, A., Hajjar, J., Gulley, J. L., Atkins, M. B., Ciliberto, G., Meric‐Bernstam, F., & Hwu, P. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001754 · Cited by 97 · see citing works
Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis
Franken, A., Mol, P. V., Vanmassenhove, S., Donders, E., Schepers, R., Brussel, T. V., Dooms, C., Yserbyt, J., Crem, N. D., Testelmans, D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005323 · Cited by 89 · see citing works
Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury
Zhang, Z., Zhou, J., Verma, V., Liu, X., Wu, M., Yu, J., & Chen, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.774807 · Cited by 95 · see citing works
Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Ramos‐Casals, M., & Sisó‐Almirall, A. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202402200 · Cited by 96 · see citing works
Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity
Farina, A., Birzu, C., Elsensohn, M., Pïcca, A., Muñiz‐Castrillo, S., Vogrig, A., Villagrán‐García, M., Ciano-Petersen, N. L., Massacesi, L., Hervier, B., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad169 · Cited by 90 · see citing works
Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations
Casagrande, S., Sopetto, G. B., Bertalot, G., Bortolotti, R., Racanelli, V., Caffo, O., Giometto, B., Berti, A., & Veccia, A. (2024) · Cancers · doi:10.3390/cancers16071440 · Cited by 92 · see citing works
Current and future immunotherapy for breast cancer
Heater, N. K., Warrior, S., & Lu, J. M. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01649-z · Cited by 93 · see citing works
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
Maulana, T. I., Kromidas, E., Wallstabe, L., Cipriano, M., Alb, M., Zaupa, C., Hudecek, M., Fogal, B., & Loskill, P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.015 · Cited by 82 · see citing works
Biomimetic Nanocarriers Guide Extracellular ATP Homeostasis to Remodel Energy Metabolism for Activating Innate and Adaptive Immunity System
Wu, L., Xie, W., Li, Y., Ni, Q., Timashev, P. S., Lyu, M., Xia, L., Zhang, Y., Liu, L., Yuan, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202105376 · Cited by 82 · see citing works
Aging-associated and CD4 T-cell–dependent ectopic CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events
Tsukamoto, H., Komohara, Y., Tomita, Y., Miura, Y., Motoshima, T., Imamura, K., Kimura, T., Ikeda, T., Fujiwara, Y., Yano, H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205378119 · Cited by 80 · see citing works
Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis
Massari, F., Mollica, V., Rizzo, A., Cosmai, L., Rizzo, M., & Porta, C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1811226 · Cited by 79 · see citing works
Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis
Chen, C., Guo, Q., Fu, H., Yu, J., Wang, L., Sun, Y., Zhang, J., & Duan, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120988 · Cited by 76 · see citing works
Transient Mild Photothermia Improves Therapeutic Performance of Oral Nanomedicines with Enhanced Accumulation in the Colitis Mucosa
Ma, Y., Gou, S., Zhu, Z., Sun, J., Shahbazi, M., Si, T., Xu, C., Ru, J., Shi, X., Reis, R. L., et al. (2023) · Advanced Materials · doi:10.1002/adma.202309516 · Cited by 72 · see citing works
Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors
Pïcca, A., Berzero, G., Bihan, K., Jachiet, V., Januel, É., Coustans, M., Cauquil, C. A., Perrin, J., Berlanga, P., Kramkimel, N., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000967 · Cited by 68 · see citing works
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
Verheijden, R. J., Burgers, F. H., Janssen, J. C., Putker, A. E., Veenstra, S., Hospers, G. A. P., Aarts, M. J. B., Hehenkamp, K. W., Doornebosch, V. L. E., Verhaert, M., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114172 · Cited by 68 · see citing works
Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions
Gang, X., Yan, J., Li, X., Shi, S., Xu, L., Liu, R. M., Cai, L., Li, H., & Zhao, M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217241 · Cited by 70 · see citing works
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Cai, X., Zhan, H., Ye, Y., Yang, J., Zhang, M., Li, J., & Zhuang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.785153 · Cited by 66 · see citing works
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
Tyan, K., Bagińska, J., Brainard, M., Giobbie‐Hurder, A., Severgnini, M., Manos, M. P., Haq, R., Buchbinder, E. I., Ott, P. A., Hodi, F. S., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02855-1 · Cited by 64 · see citing works
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Zhou, Y., Medik, Y. B., Patel, B., Zamler, D. B., Chen, S., Chapman, T., Schneider, S. M., Park, E. M., Babcock, R. L., Chrisikos, T. T., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221333 · Cited by 62 · see citing works
A Semiconducting Iron‐Chelating Nano‐immunomodulator for Specific and Sensitized Sono‐metallo‐immunotherapy of Cancer
He, S., Yu, J., Xu, M., Zhang, C., Xu, C., Cheng, P., & Pu, K. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202310178 · Cited by 60 · see citing works
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 61 · see citing works
Hybrid M13 bacteriophage-based vaccine platform for personalized cancer immunotherapy
Dong, X., Pan, P., Ye, J., Zhang, Q., & Zhang, X. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121763 · Cited by 54 · see citing works
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
Louedec, F. L., Leenhardt, F., Marin, C., Chatelut, É., Evrard, A., & Ciccolini, J. (2020) · Vaccines · doi:10.3390/vaccines8040632 · Cited by 53 · see citing works
Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?
Katsumoto, T. R., Wilson, K., Giri, V. K., Zhu, H., Anand, S., Ramchandran, K. J., Martin, B. A., Yünce, M., & Muppidi, S. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac012 · Cited by 56 · see citing works
Peripheral nervous system immune-related adverse events due to checkpoint inhibition
O’Hare, M., & Guidon, A. C. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01001-6 · Cited by 54 · see citing works
Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management
Apalla, Z., Rapoport, B. L., & Sibaud, V. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.10.005 · Cited by 52 · see citing works
Immunosuppressive Nanoparticles for Management of Immune-Related Adverse Events in Liver
Shen, S., Dai, H., Fei, Z., Chai, Y., Hao, Y., Fan, Q., Dong, Z., Zhu, Y., Xu, J., Ma, Q., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c02391 · Cited by 52 · see citing works
Autoimmune Myocarditis, Old Dogs and New Tricks.
Won, T., Song, E. J., Kalinoski, H. M., Moslehi, J. J., & Čiháková, D. (2024) · Circulation Research · doi:10.1161/circresaha.124.323816 · Cited by 51 · see citing works
Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case–control study
Kowalski, B., Valaperti, A., Bezel, P., Steiner, U. C., Scholtze, D., Wieser, S., Eisenring, M., Widmer, A., Kohler, M., & Franzen, D. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03750-z · Cited by 50 · see citing works
Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang
Ma, J., Yao, Y., Tian, Y., Chen, K., & Liu, B. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00469-5 · Cited by 49 · see citing works
Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy
Dóra, D., Bokhari, S. M. Z., Aloss, K., Takacs, P., Desnoix, J. Z., Szklenárik, G., Hurley, P. D., & Lohinai, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032769 · Cited by 47 · see citing works
Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit
Joseph, A., Simonaggio, A., Stoclin, A., Vieillard‐Baron, A., Géri, G., Oudard, S. M., Michot, J., Lambotte, O., Azoulay, É., & Lemiale, V. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00761-w · Cited by 48 · see citing works
Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
Berg, M. H., Rincon, S. V. D., & Miller, W. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003551 · Cited by 51 · see citing works
Self-citation
Self-delivery of metal-coordinated NIR-II nanoadjuvants for multimodal imaging-guided photothermal-chemodynamic amplified immunotherapy
Dai, Y., Li, X., Xue, Y., Chen, K., Jiao, G., Zhu, L., Li, M., Fan, Q., Dai, Y., Zhao, Q., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.05.032 · Cited by 47 · see citing works
Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: new horizons in immunotherapy
Gan, M., Liu, N., Li, W., Chen, M., Bai, Z., Liu, D., & Liu, S. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02193-7 · Cited by 47 · see citing works
Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention
Gao, Y., Tan, Y.-J., & Fang, J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01026-w · Cited by 47 · see citing works
Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations
Wu, L., Zhang, Z., Bai, M., Yan, Y., Yu, J., & Xu, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01139-8 · Cited by 48 · see citing works
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
Lacouture, M. E., Goleva, E., Shah, N. J., Rotemberg, V. M., Kraehenbuehl, L., Ketosugbo, K. F., Merghoub, T., Maier, T., Bang, A., Gu, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3431 · Cited by 44 · see citing works
Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer
Yu, Y., Wang, S., Su, N., Pan, S., Tu, B., Zhao, J., Shen, Y., Qiu, Q., Liu, X., Luan, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.906824 · Cited by 43 · see citing works
Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer
Han, X., Wang, M., Zheng, Y., Wang, N., Wu, Y., Ding, C., Jia, X., Yang, R., Geng, M., Chen, Z., et al. (2023) · European Radiology · doi:10.1007/s00330-023-10241-x · Cited by 41 · see citing works
The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
Tang, H. J., Zhou, J., & Bai, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.625872 · Cited by 42 · see citing works
Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management
Zhou, Y., Wang, Y., Xia, R.-L., Liu, J., & Ma, X. (2022) · International Journal of Ophthalmology · doi:10.18240/ijo.2022.04.19 · Cited by 42 · see citing works
Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Liu, C., Wei, W., Yang, L., Li, J., Cheng, Y., Pu, Y., Yin, T., Na, F., Zhang, L., Fu, P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1173952 · Cited by 43 · see citing works
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies
Sun, W., Hu, S., & Wang, X. (2024) · 癌症：英文版 · doi:10.1002/cac2.12587 · Cited by 42 · see citing works
Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade
Berner, F., Bomze, D., Lichtensteiger, C., Walter, V. P., Niederer, R., Ali, O. H., Wyss, N., Bauer, J., Freudenmann, L. K., Marcu, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn9644 · Cited by 40 · see citing works
Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice
Villagrán‐García, M., & Velasco, R. (2022) · Neurological Sciences · doi:10.1007/s10072-022-05920-4 · Cited by 43 · see citing works
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
Zubiri, L., Molina, G. E., Mooradian, M. J., Cohen, J. V., Durbin, S., Petrillo, L. A., Boland, G. M., Juric, D., Dougan, M. L., Thomas, M. F., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002886 · Cited by 38 · see citing works
CAR-NK cells in combination therapy against cancer: A potential paradigm
Li, J., Hu, H., Lian, K., Zhang, D., Hu, P., He, Z., Zhang, Z., & Wang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27196 · Cited by 40 · see citing works
Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors
Pïcca, A., Valyraki, N. E., Birzu, C., Kramkimel, N., Hermine, O., Zahr, N., Berzero, G., & Psimaras, D. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001073 · Cited by 40 · see citing works
Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors
Vilariño, N., Bruna, J., Kalofonou, F., Anastopoulou, G. G., & Argyriou, A. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165774 · Cited by 37 · see citing works
FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients
Leger, M. C., Routy, B., & Juneau, D. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.04.010 · Cited by 37 · see citing works
Self-citation
Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors
Zhao, L.-J., Li, Y., Jiang, N., Song, X., Xu, J.-H., Zhu, X.-Z., Chen, C., Kong, C., Wang, X.-H., Zong, D., et al. (2022) · Journal of immunotherapy · doi:10.1097/cji.0000000000000415 · Cited by 26 · see citing works
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors
Choi, J. N., Anderson, R., Blidner, A. G., Cooksley, T., Dougan, M. L., Glezerman, I. G., Ginex, P., Girotra, M., Gupta, D., Johnson, D. B., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05706-4 · Cited by 35 · see citing works
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 35 · see citing works
IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction
Meraviglia-Crivelli, D., Villanueva, H., Zheleva, A., Villalba-Esparza, M., Moreno, B., Menon, A. P., Calvo, A., Cebollero, J., Barainka, M., Mozos, I. R. D. L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01679-6 · Cited by 32 · see citing works
Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review
Filho, P. N., Albuquerque, C., Capella, M. P., & Debiasi, M. (2023) · Oncology and Therapy · doi:10.1007/s40487-023-00224-9 · Cited by 35 · see citing works
Progress in nanoparticle-based regulation of immune cells
Fan, Y.-N., Zhao, G., Zhang, Y., Ye, Q., Sun, Y., Shen, S., Liu, Y., Xu, C., & Wang, J. (2023) · Medical Review · doi:10.1515/mr-2022-0047 · Cited by 35 · see citing works
Harnessing myeloid cells in cancer
Park, S., Pylaeva, E., Bhuria, V., Gambardella, A. R., Schiavoni, G., Mougiakakos, D., Kim, S.-H., & Jabłońska, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02249-2 · Cited by 35 · see citing works
Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors
Mac, Q. D., Sivakumar, A., Phuengkham, H., Xu, C., Bowen, J. R., Su, F., Stentz, S. Z., Sim, H., Harris, A. M., Li, T. T., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00852-y · Cited by 35 · see citing works
Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice
Collier, J. L., Pauken, K. E., Lee, C. A. A., Patterson, D. G., Markson, S. C., Conway, T. S., Fung, M. E., France, J. A., Mucciarone, K., Lian, C. G., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221920 · Cited by 33 · see citing works
Nivolumab-associated DRESS in a genetic susceptible individual
Ai, L., Gao, J., Zhao, S., Li, Q., Cui, Y., Liu, Q., Wu, D., Wang, Y., Jin, X., Ji, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002879 · Cited by 32 · see citing works
Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology
Jamal, R., Messaoudene, M., de Figuieredo, M., & Routy, B. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101754 · Cited by 31 · see citing works
Self-citation
Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
Yan, T., Yu, L., Zhang, J., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1292122 · Cited by 34 · see citing works
Immunoregulatory effects of Huaier (Trametes robiniophila Murr) and relevant clinical applications
Long, H., & Wu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147098 · Cited by 29 · see citing works
Immune Checkpoint Blockade and Skin Toxicity Pathogenesis
Ma, B., & Anandasabapathy, N. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.06.040 · Cited by 30 · see citing works
Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
Qin, R., Jin, T., & Xu, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1326097 · Cited by 29 · see citing works

Personalized treatment of immune-related adverse events — balance is required
Martins, F., & Obéid, M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0400-4 · Cited by 7 · see citing works
Pathological perspectives on immune-related adverse events
Kubo, T., Morita, R., Sasaki, K., Shijubou, N., Murata, K., Tsukahara, T., Torigoe, T., & Hirohashi, Y. (2026) · Immunological Medicine · doi:10.1080/25785826.2026.2689102
Comprehensive management of immune-related adverse events: predictive strategies, mechanistic insights, and therapeutic approaches
Murakami, K. (2026) · Immunological Medicine · doi:10.1080/25785826.2026.2664951
Clinical and translational attributes of immune-related adverse events
Suijkerbuijk, K. P. M., van Eijs, M. J. M., van Wijk, F., & Eggermont, A. M. M. (2024) · Nature Cancer · doi:10.1038/s43018-024-00730-3 · Cited by 128 · see citing works
Immunologic adverse events from immune checkpoint therapy
Richter, M. D., Hughes, G. C., Chung, S. H., Ezeanuna, M., Singh, N., & Thompson, J. A. (2020) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2020.101511 · Cited by 6 · see citing works

Authors: Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L.
Affiliations: McGill University (CA)
Cleveland Clinic (US)
Centre Hospitalier de l’Université de Montréal (CA)
Corresponding author: Esfahani, Khashayar
ORCID: Esfahani, Khashayar
Elkrief, Arielle
Calabrese, Cassandra
Lapointe, Réjean
Hudson, Marie
Routy, Bertrand
Miller, Wilson H.
Calabrese, Leonard
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2020-04-03
Volume: 17
Issue: 8
Pages: 504-515
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/s41571-020-0352-8
OpenAlex: W3015154527
Cited by: 351
References: 187
Citations by year: 2026: 39 · 2025: 60 · 2024: 65 · 2023: 56 · 2022: 59 · 2021: 51 · 2020: 20
FWCI: 4.99
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: immune-related adverse events, immune checkpoint inhibitors, personalized treatment, immunohistopathology, immune reconstitution, tumor surveillance, autoimmune disease management, immunopathology
MeSH terms: Antineoplastic Agents, Immunological, Humans, Immunologic Factors, Immunologic Surveillance, Immunotherapy, Neoplasms, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Moving towards personalized treatments of immune-related adverse events

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks